ASPIrin in Reducing Events in Dialysis ( ASPIRED )
ASPIrin in Reducing Events in Dialysis
Guangdong Provincial People's Hospital
9,000 participants
Jul 30, 2020
INTERVENTIONAL
Conditions
Summary
People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Aspirin 100 mg tablet daily
Matching Placebo 1 pill daily
Locations(139)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04381143